Crohns logo
  Home | About Us | More Info | Articles | Archive | Product List | Store Map | SEARCH | Site Map | Why Shop
Safe Shopping Guaranteed100% Secure     Call in Your Order Mon - Fri 9AM to 5PM PST1-877-240-7528 Contact Us by e-mail Have Questions. Check out Help!Help View items in your basket Basket Shiping FAQShipping FAQ

Crohn's Disease- Pathophysiology and Conventional and Alternative Treatment Options

Crohn's Disease

Table 1: Subcategories of Crohn's Disease

Table 2: Signs and Symptoms of Crohn's Disease and Ulcerative Colitis

Risk Factors



    The Genetic Component of Crohn's Disease

    Stress in the Etiology of Crohn's Disease

    Microbial Factors

    Inflammation/Immune Response

    Intestinal Permeability

    Other Abnormalities Contributing to the Etiopathogenesis of Crohn's Disease

Conventional Treatment of Crohn's Disease

Table 5: Conventional Medications and their Mechanisms in Crohn's Disease

Nutrient Deficiences in Crohn's Disease

Table 6: nutrient Deficiencies Associated with Crohn's Disease

Dietary Interventions in Crohn's Disease

Table 7: Diet Therapies Compared to Steroid Medications in Crohn's Disease

Probiotics in the Treatment of Crohn's Disease

Fatty Acids for the Treatment of Crohn's Disease

Table 8: A Summary of Omega-3 Fatty Acid Studies in Crohn's Disease


N-acetyl Glucosamine

Remicade Increasing Risk of Cancer

Botanicals in the Treatment of Crohn's Disease

Dehydroepiandrosterone (DHEA)

Potential Sequelae of Crohn's Disease


Remicade Increasing Risk of Cancer

Journal of the American Medical Association, May 2006, cite an increased rate of several types of cancer and of serious infection with the use of Remicade and Humira. It has been known for a long time that these treatments increase the risk of certain types of cancer or infection like lymphoma and tuberculosis. However, there now appears to be an increased risk for a broader set of cancers and infections in patients undergoing medical treatment for Inflammaotry Bowel Disease.

The study examined Remicade® (infliximab), which to date is the only anti-TNF therapy that the FDA has approved for the treatment of Irritable Bowel Diseasae as well as Humira® (adalimumab), a treatment that is currently undergoing clinical trials for the treatment of Crohn's disease. The study, led by investigators at Mayo Clinic, used "meta-analysis" to combine and assess the results from a large set of clinical studies already in the literature. Less common events associated with treatment can be detected with the large number of patients and years of treatment represented by these combined studies.

Overall, the study suggests that the increased risk of cancer like lymphoma, skin, gastrointestinal, breast and lung or serious infection may be three-fold and two-fold, respectively. The risk appears to be mainly in patients receiving high dose treatment which is more than 6 mg/kg every 8 weeks; or use of Humra (adalimumab, 40 mg every other week). The increased risk of cancer occurred early, and there was not a further increase of cancer with longer times.


Call 1-877-240-7528 • Mon-Fri 9am-5pm PST
P.O. Box 927747 ~ San Diego ~ California ~ 92192 ~ USA
Home | About Us | Quick Product Links | Search | Help